Ossianix, Lundbeck in CNS deal

Ossianix Inc. (Philadelphia, Pa.) said it partnered with H. Lundbeck A/S (CSE:LUN) to discover therapeutics for CNS diseases. Ossianix raised an undisclosed amount from a convertible promissory note from Lundbeck, which will retain exclusive rights to negotiate a license on resulting products. Lundbeck also will have non-exclusive rights to negotiate a license on technologies arising from the deal. Ossianix will use its shark variable new antigen receptor (VNAR) technology to discover therapeutics to treat nervous system diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and pain. ...